Repurposing Cancer Drugs for COVID-19: Promise, Progress, and the Need for Rigorous Trials

Background

The urgent need for COVID-19 treatments led researchers to investigate repurposing existing drugs—including cancer therapies—due to their known safety profiles and potential antiviral or immunomodulatory mechanisms.

Potential Mechanisms of Action

• Direct antiviral effects: Some agents inhibit viral replication by targeting viral proteins or host factors essential for the viral life cycle (e.g., remdesivir, originally developed for hepatitis C/Ebola).
• Immunomodulatory effects: Checkpoint inhibitors (e.g., anti-PD-1/PD-L1) may enhance T-cell responses against infected cells; other agents modulate cytokine signaling.
• Anti-inflammatory effects: Targeting the "cytokine storm" driving severe COVID-19 (e.g., JAK inhibitors, IL-6 inhibitors).

Cancer Drugs Investigated for COVID-19

• Remdesivir: Originally an investigational antiviral for Ebola; received FDA approval for hospitalized COVID-19 patients, reducing recovery time.
• Hydroxychloroquine/chloroquine: Early in vitro promise, but large randomized trials (RECOVERY, SOLIDARITY) showed no clinical benefit and potential cardiac toxicity.
• Imatinib: A tyrosine kinase inhibitor for CML; demonstrated SARS-CoV-2 replication inhibition in vitro; clinical trials ongoing.
• Tocilizumab (IL-6 receptor antagonist): Approved for hospitalized patients with systemic inflammation; improves survival in specific subgroups.
• Baricitinib (JAK inhibitor): Authorized in combination with remdesivir for hospitalized patients requiring oxygen.

Conclusion

Drug repurposing is a valuable strategy for rapid response, but rigorous randomized controlled trials are essential to establish efficacy, safety, optimal dosing, and patient selection. Many early candidates failed in late-stage trials. Research continues exploring other oncology agents and combination strategies.